aTyr Pharma Statistics
Total Valuation
aTyr Pharma has a market cap or net worth of $549.71 million. The enterprise value is $482.04 million.
Important Dates
The last earnings date was Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
aTyr Pharma has 97.99 million shares outstanding. The number of shares has increased by 31.11% in one year.
| Current Share Class | 97.99M |
| Shares Outstanding | 97.99M |
| Shares Change (YoY) | +31.11% |
| Shares Change (QoQ) | +4.20% |
| Owned by Insiders (%) | 2.06% |
| Owned by Institutions (%) | 68.78% |
| Float | 95.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.96 |
| P/TBV Ratio | 7.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.63, with a Debt / Equity ratio of 0.17.
| Current Ratio | 5.63 |
| Quick Ratio | 5.21 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -85.39% and return on invested capital (ROIC) is -47.95%.
| Return on Equity (ROE) | -85.39% |
| Return on Assets (ROA) | -42.20% |
| Return on Invested Capital (ROIC) | -47.95% |
| Return on Capital Employed (ROCE) | -81.45% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.03M |
| Employee Count | 65 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +216.95% in the last 52 weeks. The beta is 1.01, so aTyr Pharma's price volatility has been similar to the market average.
| Beta (5Y) | 1.01 |
| 52-Week Price Change | +216.95% |
| 50-Day Moving Average | 5.33 |
| 200-Day Moving Average | 4.08 |
| Relative Strength Index (RSI) | 56.46 |
| Average Volume (20 Days) | 4,165,265 |
Short Selling Information
The latest short interest is 28.25 million, so 28.83% of the outstanding shares have been sold short.
| Short Interest | 28.25M |
| Short Previous Month | 25.60M |
| Short % of Shares Out | 28.83% |
| Short % of Float | 29.43% |
| Short Ratio (days to cover) | 4.94 |
Income Statement
| Revenue | n/a |
| Gross Profit | -54.23M |
| Operating Income | -70.05M |
| Pretax Income | -53.93M |
| Net Income | -66.64M |
| EBITDA | -69.36M |
| EBIT | -70.05M |
| Earnings Per Share (EPS) | -$0.80 |
Full Income StatementBalance Sheet
The company has $80.35 million in cash and $12.68 million in debt, giving a net cash position of $67.67 million or $0.69 per share.
| Cash & Cash Equivalents | 80.35M |
| Total Debt | 12.68M |
| Net Cash | 67.67M |
| Net Cash Per Share | $0.69 |
| Equity (Book Value) | 74.66M |
| Book Value Per Share | 0.81 |
| Working Capital | 71.96M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$55.60 million and capital expenditures -$49,000, giving a free cash flow of -$55.65 million.
| Operating Cash Flow | -55.60M |
| Capital Expenditures | -49,000 |
| Free Cash Flow | -55.65M |
| FCF Per Share | -$0.57 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
aTyr Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -31.11% |
| Shareholder Yield | -31.11% |
| Earnings Yield | -12.12% |
| FCF Yield | -10.12% |
Analyst Forecast
The average price target for aTyr Pharma is $23.25, which is 314.44% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $23.25 |
| Price Target Difference | 314.44% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 371.98% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 1, 2019. It was a reverse split with a ratio of 1:14.
| Last Split Date | Jul 1, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:14 |
Scores
aTyr Pharma has an Altman Z-Score of -3.48 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.48 |
| Piotroski F-Score | 1 |
